Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications

Journal of Proteomics

Volumn 108, Issue , 2014, Pages 171-187

  Walsh, Joanne ^a   Jenkins, Rosalind E ^a   Wong, Michael ^a   Olayanju, Adedamola ^a   Powell, Helen ^b   Copple, Ian ^a   O'Neill, Paul M ^a   Goldring, Christopher E P ^a   Kitteringham, Neil R ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

CDDO; CYP2A5; ENTPD5; Hepatoproteome; ITRAQ; Nrf2

Indexed keywords

BARDOXOLONE METHYL; BIOLOGICAL MARKER; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2A5; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE TYPE 5; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE A4; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; PHOSPHATASE; PROTEOME; RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE; CYTOSKELETON PROTEIN; KEAP1 PROTEIN, MOUSE; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; NFE2L2 PROTEIN, MOUSE; OLEANOLIC ACID; OXIDOREDUCTASE; PROTEIN KINASE B; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENHANCER REGION; IMMUNOBLOTTING; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; MALE; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OXIDOREDUCTASES; PROTEOME; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84902289343     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.05.007     Document Type: Article

References (58)

1. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003, 8:379-391.
2. Tong K.I., Kobayashi A., Katsuoka F., Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 2006, 387:1311-1320.
3. Kitteringham N.R., Abdullah A., Walsh J., Randle L., Jenkins R.E., Sison R., et al. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J. Proteome 2010, 73:1612-1631.
4. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002, 62:5196-5203.
5. Chan K., Han X.D., Kan Y.W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001, 98:4611-4616.
6. Enomoto A., Itoh K., Nagayoshi E., Haruta J., Kimura T., O'Connor T., et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001, 59:169-177.
7. Xu W., Hellerbrand C., Kohler U.A., Bugnon P., Kan Y.W., Werner S., et al. The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest 2008, 88:1068-1078.
8. Lamle J., Marhenke S., Borlak J., von Wasielewski R., Eriksson C.J., Geffers R., et al. Nuclear factor-erythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008, 134:1159-1168.
9. Cho H.Y., Reddy S.P., Yamamoto M., Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004, 18:1258-1260.
10. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm Pharmacol Ther 2009, 22:221-236.
11. Khor T.O., Huang M.T., Kwon K.H., Chan J.Y., Reddy B.S., Kong A.N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006, 66:11580-11584.
12. Hu R., Xu C., Shen G., Jain M.R., Khor T.O., Gopalkrishnan A., et al. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci 2006, 79:1944-1955.
13. Nair S., Xu C., Shen G., Hebbar V., Gopalakrishnan A., Hu R., et al. Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Toxicol Lett 2007, 168:21-39.
14. Honda T., Rounds B.V., Gribble G.W., Suh N., Wang Y., Sporn M.B. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998, 8:2711-2714.
15. Honda T., Rounds B.V., Bore L., Favaloro F.G., Gribble G.W., Suh N., et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999, 9:3429-3434.
16. Place A.E., Suh N., Williams C.R., Risingsong R., Honda T., Honda Y., et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003, 9:2798-2806.
17. Dinkova-Kostova A.T., Liby K.T., Stephenson K.K., Holtzclaw W.D., Gao X., Suh N., et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005, 102:4584-4589.
18. Liby K., Hock T., Yore M.M., Suh N., Place A.E., Risingsong R., et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005, 65:4789-4798.
19. Yates M.S., Tauchi M., Katsuoka F., Flanders K.C., Liby K.T., Honda T., et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007, 6:154-162.
20. Pergola P.E., Raskin P., Toto R.D., Meyer C.J., Huff J.W., Grossman E.B., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011, 365:327-336.
21. Tayek J.A., Kalantar-Zadeh K. The extinguished BEACON of bardoxolone: not a Monday morning quarterback story. Am J Nephrol 2013, 37:208-211.
22. Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012, 64:972-1003.
23. Wang Y., Porter W.W., Suh N., Honda T., Gribble G.W., Leesnitzer L.M., et al. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 2000, 14:1550-1556.
24. Liby K., Voong N., Williams C.R., Risingsong R., Royce D.B., Honda T., et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006, 12:4288-4293.
25. Ahmad R., Raina D., Meyer C., Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008, 68:2920-2926.
26. Shishodia S., Sethi G., Konopleva M., Andreeff M., Aggarwal B.B. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006, 12:1828-1838.
27. Ahmad R., Raina D., Meyer C., Kharbanda S., Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006, 281:35764-35769.
28. Yore M.M., Liby K.T., Honda T., Gribble G.W., Sporn M.B. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 2006, 5:3232-3239.
29. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313-322.
30. McMahon M., Itoh K., Yamamoto M., Chanas S.A., Henderson C.J., McLellan L.I., et al. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001, 61:3299-3307.
31. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
32. Team RDC R: a language and environment for statistical computing 2005, R Foundation for Statistical Computing, Vienna, Austria.
33. Yates M.S., Tran Q.T., Dolan P.M., Osburn W.O., Shin S., McCulloch C.C., et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009, 30:1024-1031.
34. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
35. Lu H., Cui W., Klaassen C.D. Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. Toxicol Appl Pharmacol 2011, 256:122-135.
36. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
37. Tanaka Y., Aleksunes L.M., Yeager R.L., Gyamfi M.A., Esterly N., Guo G.L., et al. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 2008, 325:655-664.
38. Shin S., Wakabayashi J., Yates M.S., Wakabayashi N., Dolan P.M., Aja S., et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 2009, 620:138-144.
39. Abu-Bakar A., Lamsa V., Arpiainen S., Moore M.R., Lang M.A., Hakkola J. Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2. Drug Metab Dispos 2007, 35:787-794.
40. Chan K., Kan Y.W. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci U S A 1999, 96:12731-12736.
41. Thimmulappa R.K., Scollick C., Traore K., Yates M., Trush M.A., Liby K.T., et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun 2006, 351:883-889.
42. de Zeeuw D., Akizawa T., Agarwal R., Audhya P., Bakris G.L., Chin M., et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol 2013, 37:212-222.
43. Bar-Or A., Gold R., Kappos L., Arnold D.L., Giovannoni G., Selmaj K., et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol 2013, 260:2297-2305.
44. Vasiliou V., Qamar L., Pappa A., Sophos N.A., Petersen D.R. Involvement of the electrophile responsive element and p53 in the activation of hepatic stellate cells as a response to electrophile menadione. Arch Biochem Biophys 2003, 413:164-171.
45. Yeligar S.M., Machida K., Kalra V.K. Ethanol-induced HO-1 and NQO1 are differentially regulated by HIF-1alpha and Nrf2 to attenuate inflammatory cytokine expression. J Biol Chem 2010, 285:35359-35373.
46. Malhotra D., Portales-Casamar E., Singh A., Srivastava S., Arenillas D., Happel C., et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010, 38:5718-5734.
47. Ji Y., Lee H.J., Goodman C., Uskokovic M., Liby K., Sporn M., et al. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther 2006, 5:1452-1458.
48. Suh N., Roberts A.B., Birkey Reffey S., Miyazono K., Itoh S., ten Dijke P., et al. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 2003, 63:1371-1376.
49. Wu Q.Q., Wang Y., Senitko M., Meyer C., Wigley W.C., Ferguson D.A., et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol 2011, 300:F1180-F1192.
50. Lamsa V., Levonen A.L., Leinonen H., Yla-Herttuala S., Yamamoto M., Hakkola J. Cytochrome P450 2A5 constitutive expression and induction by heavy metals is dependent on redox-sensitive transcription factor Nrf2 in liver. Chem Res Toxicol 2010, 23:977-985.
51. Yokota S., Higashi E., Fukami T., Yokoi T., Nakajima M. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem Pharmacol 2011, 81:289-294.
52. Hakooz N., Hamdan I. Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab 2007, 8:9-15.
53. Satarug S., Nishijo M., Ujjin P., Vanavanitkun Y., Baker J.R., Moore M.R. Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers. Environ Health Perspect 2004, 112:1512-1518.
54. Kim S.D., Antenos M., Squires E.J., Kirby G.M. Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. Toxicol Appl Pharmacol 2013, 270:129-138.
55. Okawa H., Motohashi H., Kobayashi A., Aburatani H., Kensler T.W., Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 2006, 339:79-88.
56. Bayley J.P., Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012, 24:62-67.
57. Fang M., Shen Z., Huang S., Zhao L., Chen S., Mak T.W., et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010, 143:711-724.
58. Read R., Hansen G., Kramer J., Finch R., Li L., Vogel P. Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5)-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest. Vet Pathol 2009, 46:491-504.